

18 November 2020 EMA/HMPC/475451/2020 Committee on Herbal Medicinal Products (HMPC)

Addendum to Assessment report on *Syzygium* aromaticum (L.) Merill et L. M. Perry, floris aetheroleum

Rapporteur(s)	R Länger
Peer-reviewer	E Svedlund
HMPC decision on review of monograph	40.0 1 2044
Syzygium aromaticum (L.) Merill et L. M. Perry, floris aetheroleum adopted on September 2011	13 September 2011
Call for scientific data (start and end date)	From 01/02/2020 to 30/04/2020
Adoption by Committee on Herbal Medicinal Products (HMPC)	18 November 2020
Review of new data on <i>Syzygium aron</i> floris aetheroleum Periodic review (from 2011 to 2020)	naucum (L.) Merm et L. M. Perry,
Periodic review (from 2011 to 2020)	
Scientific data (e.g. non-clinical and clinical safety of	
_	EudraVigilance, VigiBase, national databases)
	s: Scopus (key words 'Syzygium aromaticum AND
•	20, in total 859 hits, 595 documents published
between 2010 and 2020, 5 references consi	dered relevant.
Regulatory practice	
	fulfilling 20/15 years on the market)
☐ Old market overview in AR (i.e. products	covigilance actions taken in member states)
Referral	covigilance actions taken in member states)
☐ Ph.Eur. monograph	
Other	





☐ Public statements or other decisions taken by HMPC		
☐ Consistency with other monographs within the therapeutic area		
☐ Other		
Other		
Availability of new information (i.e. likely to lead to a relevant change of th	e monog	raph)
Scientific data	Yes	No
New non-clinical safety data likely to lead to a relevant change of the monograph		\boxtimes
New clinical safety data likely to lead to a relevant change of the monograph		
New data introducing a possibility of a new list entry		
New clinical data regarding the paediatric population or the use during pregnancy and lactation likely to lead to a relevant change of the monograph		\boxtimes
New clinical studies introducing a possibility for new WEU indication/preparation		
Other scientific data likely to lead to a relevant change of the monograph		\boxtimes
Regulatory practice	Yes	No
New herbal substances/preparations with 30/15 years of TU		
New herbal substances/preparations with 10 years of WEU		
Other regulatory practices likely to lead to a relevant change of the monograph		
Referrals likely to lead to a relevant change of the monograph		\boxtimes
New / Updated Ph. Eur. monograph likely to lead to a relevant change of the monograph		
Consistency	Yes	No
New or revised public statements or other HMPC decisions likely to lead to a		\boxtimes

Summary and conclusions on the review

relevant change of the monograph

require a change of the monograph

During the review 595 new references not yet available during the first/previous assessment were identified.

0 references were provided by Interested Parties during the Call for data.

Other relevant inconsistencies that require a change of the monograph

Relevant inconsistencies with other monographs within the therapeutic area that

5 references were considered to be relevant for the assessment.

0 references justify a revision of the monograph.

П

 \boxtimes

 \boxtimes

In a review by El-Saber *et al.*, 2020, the phytochemical composition and biological activities of clove extracts along with clove essential oil and the main active compound, eugenol, were examined and implicates new findings from gas chromatography-mass spectroscopy (GC-MS) analysis.

Srinath, 2014, reviewed the uses of selected spices like *Curcuma longa*, *Zingiber officinale*, *Piper nigrum*, *Elettaria cardamomum*, *Cinnamomum verum*, *Syzygium aromaticum*, *Trigonella foenum graecum*, *Myristica fragrans* and their applications in dentistry.

Moon et al., 2011 reported that the antibacterial activity of clove oil was higher than b-caryophyllene but was similar to eugenol against all tested oral bacteria. Furthermore, the MIC and MBC were reduced to one half-one sixteenth as a result of the combination of clove oil or eugenol with antibiotics. The synergistic interaction was verified by time kill studies using the clove oil or eugenol with antibiotics. 60 minutes of treatment with MIC of the clove oil or eugenol with ampicillin or gentamicin resulted in an increase in the rate of killing in units of CFU/mL to a greater degree than was observed with alone.

In the study by Shoeibi *et al.*, 2009, an AMES test using Salmonella typhimurium TA 100 with and without S9 mix, concentrations 50-2000 μ g/ml, showed negative results without S9 mix, but with S9 mix a dose related positive response were identified. The test is not a full test compliant with current guidelines i.e. additional bacterial strains are required.

Shalaby *et al.*, 2011, have determined the LD50 (oral administration) of clove oil to 3,597.5 mg/kg BW. At 1/10 of LD50 (every third day for one months) significant changes of white blood cell counts, decrease of haemoglobin concentration, increase of liver enzymes, creatinine and urea concentrations.

Pharmacovigilance database: 14 entries, 4 entries refer to allergic reactions caused by application of clove oil; other entries refer to administration of several drugs where the causality regarding clove oil is not clear. Mucosal irritation and allergic reactions are already mentioned in the monograph.

No revision is considered required because no relevant new references were found and no pharmacovigilance actions were taken.

References

a) References relevant for the assessment:

Shoeibi S, Rahimifard N, Pirouz B *et al*. Mutagenicity of four natural flavors: clove, cinnamon, thyme and *Zataria multiflora* Boiss. *J Med Plants* 2009, 8(Supp. 5): 89-96:

Moon S-E, Kim H-Y, Cha J-D. synergistic effect between close oil and its major compounds and antibiotics against oral bacteria. *Arch Oral Biol* 2011, 56:907-916

Shalaby SEM, El-Din MM, Abo-Donia SA, Mettwally M, Attia ZA. Toxicological affects of essential oils from Eucalyptus *Eucalyptus globules* and Clove *Eugenia caryophyllus* on albino rats. *Polish J Environ Stud* 2011, 20:429-434

Srinath J. Application of spices in dentistry- A literature review. Int J Drug Dev Res 2014, 6:1-9

El-Saber Batiha G, Alkazami LM, Wasef LG *et al. Syzygium aromaticum* L. (Myrtaceae): traditional uses, bioactive chemical constituents, pharmacological and toxicological activities. *Biomolecules* 2020, 10: 202 (16 pages)

b) References that justify the need for the revision of the monograph:

None

Rapporteur's proposal on revision
☐ Revision needed, i.e. new data/findings of relevance for the content of the monograph
$oxed{\boxtimes}$ No revision needed, i.e. no new data/findings of relevance for the content of the monograph
HMPC decision on revision
☐ Revision needed, i.e. new data/findings of relevance for the content of the monograph
oximes No revision needed, i.e. no new data/findings of relevance for the content of the monograph
The HMPC agreed not to revise the monograph, assessment report and list of references on <i>Syzygium aromaticum</i> (L.) Merill et L. M. Perry, floris aetheroleum, by consensus.